Carboplatin As Effective As Standard Combination Therapy For Advanced Ovarian Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Carboplatin As Effective As Standard Combination Therapy For Advanced Ovarian Cancer

LONDON, ENGLAND -- Nov. 13, 1998 -- Chemotherapy is commonly used after surgery to treat ovarian cancer. The ideal drug doses and combinations for chemotherapy are a source of constant debate and which permutation forms the standard regimen changes frequently.

In the ICON2 trial, a research team co-ordinated by Dr. Mahesh Parmar from the cancer division of the MRC Clinical Trials Unit in Cambridge, England, compared a drug called carboplatin with a commonly used combined regimen consisting of three drugs: cyclophosphamide, doxorubicin and cisplatin (CAP).

In this week's issue of The Lancet, they report that carboplatin was just as effective and substantially less toxic, than CAP.

Between January 1991 and July 1996, 1,526 women were enrolled into 132 study centres in nine countries. All women had been diagnosed with ovarian cancer. The women were allocated at random to be given six cycles of either carboplatin or CAP, with three-week intervals. The dose of carboplatin was calculated mathematically (by the area-under-the-curve method). The CAP regimen consisted of cyclophosphamide 500 mg/m2, doxorubicin 50 mg/m2 and cisplatin 50 mg/m2. Data were collected at randomisation, six months, 12 months and annually thereafter.

By February 1998, 728 women had died -- 368 in the CAP group and 360 in the carboplatin group, suggesting equivalent risks of death in the two groups.

"We found no evidence of a difference in progression-free or overall survival between CAP and carboplatin," the investigators write. However, carboplatin proved less toxic than CAP, causing less alopecia (baldness), leucopenia (white blood cell deficiency), nausea and vomiting. Carboplatin caused more thrombocytopenia (low number of platelets in the blood).

"Carboplatin is a safe, effective and appropriate standard treatment for women with advanced ovarian cancer," they write.

Related Links: The Lancet

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities